| Name | Title | Contact Details |
|---|---|---|
David Maris |
CTO Office Enterprise Architect | Profile |
Fatema Mathur |
Associate Director, IT Medicine | Profile |
Siddharth Dixit |
Executive Director, HP Commercial & Medicine Data & Analytics, IT Enterprise Data, AI & Platforms | Profile |
Bhawna Paul |
Head of Information Technology Strategy | Profile |
Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.
Accent Urgent Care and After Hours Pediatrics is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oak Hill Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Oak Hill Hospital is based in Brooksville, FL. You can find more information on Oak Hill Hospital at www.oakhillhospital.com
Downey Regional Medical Center, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Downey Regional Medical Center, Inc. is based in Downey, CA. You can find more information on Downey Regional Medical Center, Inc. at www.drmci.org
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.